A candidate mouse model for Hartnup disorder deficient in neutral amino acid transport.
The mutant mouse strain HPH2 (hyperphenylalaninemia) was isolated after N-ethyl-N-nitrosourea (ENU) mutagenesis on the basis of delayed plasma clearance of an injected load of phenylalanine. Animals homozygous for the recessive hph2 mutation excrete elevated concentrations of many of the neutral amino acids in the urine, while plasma concentrations of these amino acids are normal. In contrast, mutant homozygotes excrete normal levels of glucose and phosphorus. These data suggest an amino acid transport defect in the mutant, confirmed in a small reduction in normalized values of 14C-labeled glutamine uptake by kidney cortex brush border membrane vesicles (BBMV). The hyperaminoaciduria pattern is very similar to that of Hartnup Disorder cases also show niacin deficiency symptoms, of Hartnup Disorder cases also show niacin deficiency symptoms, which are thought to be multifactorially determined. Similarly, the HPH2 mouse exhibits a niacin-reversible syndrome that is modified by diet and by genetic background. Thus, HPH2 provides a candidate mouse model for the study of Hartnup Disorder, an amino acid transport deficiency and a multifactorial disease in the human.
Symula
D J
DJ
McArdle Laboratory for Cancer Research, University of Wisconsin, Madison 53706, USA.
Shedlovsky
A
A
Guillery
E N
EN
Dove
W F
WF
D000818:Animals; D001692:Biological Transport; D001786:Blood Glucose / Q000032:analysis; D004195:Disease Models, Animal; D006029:Glycosuria; D006250:Hartnup Disease / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007668:Kidney / Q000378:metabolism; D051379:Mice; D010649:Phenylalanine / Q000378:metabolism*
D001786:Blood Glucose; D010649:Phenylalanine